Vivimed Labs.

- Healthcare (Pharma) segment expected to continue strong growth, driven by API business (UQUIFA) and growing CMO pipeline with new/existing customers. - 22% YoY growth achieved in healthcare segment in Q1 FY2017; pharma revenue now approx. 78% of total consolidated sales. - Anticipated increase in US generic formulations sales with 3 products already commercialized and 2 more expected before end of calendar year. - Alathur facility's revenue expected to significantly increase over next 24 months (currently $5-6 million annually). - Specialty Chemicals business undergoing transition post divestiture; residual business estimated around Rs. 250 crores with EBIT margins ~18-20%. - CIS countries revenue expected this fiscal; orders received starting Q2. - R&D and new product filings expected to boost pharma business, with 5 incremental filings targeted before March 2017. - Overall revenue growth supported by pipeline, product introductions, and improved capacity utilization in pharma and CMO businesses.

- Vivimed Labs expects interesting growth prospects in the pharma business, particularly in the FDF (Finished Dosage Formulations) generic segment with significant investments of Rs. 150-200 crores to drive revenue growth over the next 12-24 months. - The API and Contract Manufacturing Organization (CMO) businesses are gaining traction with more customers and pipeline opportunities, contributing to growth. - R&D spend is increasing due to more product filings (DMF/ANDA) aiming for new product launches, supporting medium-to-long-term growth. - Specialty chemicals business is currently downsized but new products are expected in the pipeline, with EBIT margins around 18-20%. - EBITDA margins on pharma are stable with an 82 basis points sequential increase; margins expected to be maintained at current levels. - EPS and profitability are expected to improve with these growth drivers and reduced finance costs due to debt repayment initiatives.

- The company has a reasonably strong CMO (Contract Manufacturing Organization) pipeline with new projects from existing clients as well as new customers (Page 4). - CMO business is expected to grow to be a larger part of the pharma segment revenues (Page 4). - The filing pipeline for generic products is active with an expectation to complete an incremental 5 new filings before March 2017 (Page 4). - There is good traction in API and CMO business, and customers are coming back with more business and pipeline opportunities (Page 15). - Growth and revenues from the Alathur facility are expected to significantly increase over the next 24 months (Page 7). - Orders from CIS countries started coming in the second quarter with more products expected, aligning with the budgeted CIS revenues for the year (Page 7).

- As of Q1 FY2017, there is no explicit mention of new fundraising through debt or equity in the transcript. - The company is working on repaying existing debt, with a commitment to repay roughly Rs. 50-60 crores annually over the next 4 years. - They are actively negotiating with a PE investor in UQUIFA for a buyout or alternate investor to take the position. - Discussions are ongoing to manage the PE investor's exit by the end of the current year. - The company is focusing on monetizing land assets (part of the SEZ) to reduce debt further. - No concrete plans for fresh equity issuance were disclosed; the focus is on managing existing financial obligations and improving cash flow through asset sales.

- The company has spent on CAPEX primarily in the Alathur facility to increase capacity. - Investment aimed at boosting new product filings in both formulations and APIs. - Focus on pharmaceutical business expansion, particularly in Fixed Dosage Formulations (FDF) and API/CMO businesses. - No specific new large-scale capital investments announced, but ongoing investments in R&D and product filings continue. - Anticipated revenues and capacity utilization growth from Alathur facility over next 24 months, implying continued investment there. - Plans to utilize divestment proceeds (e.g., from Clariant deal) partly for CAPEX alongside debt reduction and taxes. - Strategic focus on new product development and enhancing pharma business, signaling potential future capital allocation towards these areas.